Immunotherapeutics for the treatment of prostate cancer: A patent landscape based on key therapeutic mechanisms of actions

Elaine Harris

doi:10.4155/ppa-2017-0029

Immunotherapeutics for the treatment of prostate cancer: A patent landscape based on key therapeutic mechanisms of actions

Research output: Contribution to journal › Review article › peer-review

Abstract

The area of immunotherapeutics for the treatment of metastatic castrate-resistant prostate cancer has made significant progress since the autologous cell-based vaccine sipuleucel T became the first and to date only immunotherapy for its treatment. This review focuses on a broad patent landscaping exercise of this therapeutic area and considers if basing this landscaping on key mechanisms of action is appropriate to elicit the main patenting trends.

Original language	English
Pages (from-to)	47-57
Number of pages	11
Journal	Pharmaceutical Patent Analyst
Volume	7
Issue number	1
DOIs	https://doi.org/10.4155/ppa-2017-0029
Publication status	Published - Jan 2018
Externally published	Yes

Keywords

immunotherapeutics
immunotherapy
metastatic castration-resistant prostate cancer (mCRPC)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4155/ppa-2017-0029

Cite this

@article{a0b341f5640c4985b1c1df49ce24210e,

title = "Immunotherapeutics for the treatment of prostate cancer: A patent landscape based on key therapeutic mechanisms of actions",

abstract = "The area of immunotherapeutics for the treatment of metastatic castrate-resistant prostate cancer has made significant progress since the autologous cell-based vaccine sipuleucel T became the first and to date only immunotherapy for its treatment. This review focuses on a broad patent landscaping exercise of this therapeutic area and considers if basing this landscaping on key mechanisms of action is appropriate to elicit the main patenting trends.",

keywords = "immunotherapeutics, immunotherapy, metastatic castration-resistant prostate cancer (mCRPC)",

author = "Elaine Harris",

note = "Publisher Copyright: {\textcopyright} 2018 2017 Future Science Ltd.",

year = "2018",

month = jan,

doi = "10.4155/ppa-2017-0029",

language = "English",

volume = "7",

pages = "47--57",

journal = "Pharmaceutical Patent Analyst",

issn = "2046-8954",

publisher = "Taylor and Francis Ltd.",

number = "1",

}

TY - JOUR

T1 - Immunotherapeutics for the treatment of prostate cancer

T2 - A patent landscape based on key therapeutic mechanisms of actions

AU - Harris, Elaine

PY - 2018/1

Y1 - 2018/1

N2 - The area of immunotherapeutics for the treatment of metastatic castrate-resistant prostate cancer has made significant progress since the autologous cell-based vaccine sipuleucel T became the first and to date only immunotherapy for its treatment. This review focuses on a broad patent landscaping exercise of this therapeutic area and considers if basing this landscaping on key mechanisms of action is appropriate to elicit the main patenting trends.

AB - The area of immunotherapeutics for the treatment of metastatic castrate-resistant prostate cancer has made significant progress since the autologous cell-based vaccine sipuleucel T became the first and to date only immunotherapy for its treatment. This review focuses on a broad patent landscaping exercise of this therapeutic area and considers if basing this landscaping on key mechanisms of action is appropriate to elicit the main patenting trends.

KW - immunotherapeutics

KW - immunotherapy

KW - metastatic castration-resistant prostate cancer (mCRPC)

UR - https://www.scopus.com/pages/publications/85050186463

U2 - 10.4155/ppa-2017-0029

DO - 10.4155/ppa-2017-0029

M3 - Review article

C2 - 29227196

AN - SCOPUS:85050186463

SN - 2046-8954

VL - 7

SP - 47

EP - 57

JO - Pharmaceutical Patent Analyst

JF - Pharmaceutical Patent Analyst

IS - 1

ER -

Immunotherapeutics for the treatment of prostate cancer: A patent landscape based on key therapeutic mechanisms of actions

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this